Presented by Michelle Papka, Ph.D.
Founder and President
The Cognitive and Research Center of New Jersey, LLC.
Alzheimer’s disease treatment and diagnosis has been increasingly in the news. Several prescription drugs to treat the symptoms of the disease have been available for many years. Recently (Aduhelm in 2021 and Leqembi in 2023), the U.S. Food and Drug Administration (FDA) gave full approval for the first disease modifying drugs. In addition, more potential medications and diagnostic tools are currently under scientific investigation. In our upcoming guest speaker webinar, Michelle Papka, Ph.D., will discuss FDA-approved medications as well as those currently under investigation. Dr. Papka will also review exciting new advances in identifying biomarkers for Alzheimer’s disease, the importance of clinical trials, and what lies ahead for the future of Alzheimer’s disease research.